drugset
drugset / Trial / NCT06544265

SynKIR-310 for Relapsed/Refractory B-NHL

NCT06544265 ↗

Phase 1 Recruiting 36 enrolled Verismo Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

Timeline

Start
2024-11-01
Primary completion
2028-09
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject SynKIR-310 Cell therapy — Intravenous

Indications

T-cell/histiocyte rich large B cell lymphoma Waldenstrom macroglobulinemia diffuse large B-cell lymphoma with chronic inflammation follicular lymphoma high grade B-cell lymphoma high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement large B-cell lymphoma mantle cell lymphoma primary mediastinal large B-cell lymphoma splenic marginal zone lymphoma